XBIT News and Press, XBiotech Inc. From 02/13/20

AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020. Based on the pre...

On Tuesday, XBiotech Inc. ( XBIT ) rose 31% to $24.33 after the company announced that it intends to proceed with a partial tender offer of its shares in the $30 to $33 range for $420 million. It followed that up with another green day on Wednesday to close at $24.94, which is still a 20% di...

After the company announced that it will repurchase up to $420 million of its shares at a price no lower than $30 nor higher than $33 apiece, shares in XBiotech (NASDAQ: XBIT) are surging 32.7% higher at 3:00 pm EST on Tuesday. The share repurchase follows Johnson & Johnson 's (NYSE: ...

RTI Surgical Holdings (NASDAQ: RTIX ) +105%  on sale of OEM business . More news on: RTI Surgical Holdings, Inc., TransEnterix, Inc., XBiotech Inc., Stocks on the move, , Read more ...

AUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are pr...

2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...

XBiotech (NASDAQ: XBIT ) +1.8% after-hours following news it closed the sale of its True Human antibody bermekimab to Johnson & Johnson's Janssen Biotech unit. More news on: XBiotech Inc., Healthcare stocks news, Stocks on the move, Read more ...

AUSTIN, Texas, Dec. 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today closing of the sale of the Company’s True Human antibody Bermekimab to Janssen Biotech, Inc. (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson. Upon closing, Janssen paid ...

XBiotech ( XBIT ) surged higher recently after the company announced a massive out-licensing deal worth $1.35 billion based on its antibody drug Bermekimab. Xbiotech had made a deal with Johnson & Johnson ( JNJ ) to outlicense its product Bermekimab, which is being developed to t...

AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019. T...